A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation Curaderm~(BEC5)

摘要

New approaches to curb developmental and end-stage production expenses, whilst generating a safe and effective treatment for cancer, resulting in lower cost for the patient and healthcare system, are warranted. A bioassay-guided fractionation of a Solanum plant, S. sodomaeum, to a standardized extract can be classified as a new drug. It is shown that a specific standardized plant extract, BEC, containing a given concentration of a target efficacious and safe compound, solamargine, is an acceptable anticancer and less costly chemotherapeutic reality.